Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction
| Autor: | Marta Noris Mora, Pere Pericas, Vicente Peral Disdier, Xavier Rossello, Caterina Mas-Lladó, Rosa González Colino, José Francisco Forteza Albertí, Maria F Ramis-Barceló, Isabel Valadrón, Lucía Pasamar Márquez |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Time Factors Diastole Tetrazoles Sacubitril Ventricular Function Left 03 medical and health sciences 0302 clinical medicine Internal medicine Internal Medicine medicine Humans Protease Inhibitors Longitudinal Studies Prospective Studies Aged Heart Failure Ejection fraction business.industry Aminobutyrates Biphenyl Compounds Stroke Volume Recovery of Function Middle Aged medicine.disease Drug Combinations 030104 developmental biology medicine.anatomical_structure Treatment Outcome Valsartan Ventricle Echocardiography Heart failure Cohort Cardiology Female Neprilysin Cardiology and Cardiovascular Medicine business Angiotensin II Type 1 Receptor Blockers 030217 neurology & neurosurgery Sacubitril Valsartan medicine.drug |
| Zdroj: | High blood pressurecardiovascular prevention : the official journal of the Italian Society of Hypertension. 28(2) |
| ISSN: | 1179-1985 |
| Popis: | Sacubitril/valsartan (S–V) has been shown to reduce clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been mostly attributed to an improvement in systolic function. This study aimed to evaluate longitudinal changes in several echocardiographic parameters of diastolic function in a cohort of patients with HFrEF receiving S–V. Echocardiographic parameters of consecutive patients receiving S–V, such as diastolic dysfunction (DD) grade and other individual diastolic and systolic function parameters, were prospectively collected at baseline and at 6-month follow-up. New York Heart Association (NYHA) functional class was also recorded. 65 patients (73.9% males; 61.5 ± 13 years) with HFrEF in NYHA class II–IV were evaluated. There was a significant reduction in DD grade after treatment with maximal tolerated doses (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink